20,000-square-foot site increases Endo’s sterile injectable production capacity This marks the site’s first U.S. FDA approval Endo is investing and innovating in its Injectable Solutions business MALVERN, Pa., Dec. 9, 2024 /PRNewswire/ — Endo, Inc. […]
MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ — Endo, Inc. (“Endo”) (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren’s contracture patient journey, including his treatment with XIAFLEX® (collagenase clostridium histolyticum) […]
MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics (“MC2”) to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through […]
MALVERN, Pa., Aug. 7, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) (“Endo” or the “Company”) announced today that it will release its second quarter 2024 financial results on August 27, 2024, prior to market open. […]
